<p>New techniques and approaches for organic synthesis, purification and biological testing are enabling pharmaceutical industries to produce and test increasing numbers of compounds every year. Surprisingly, this has not led to more new drugs reaching the market, prompting two questions – why is there not a better correlation between their efforts and output, and can it be improved? One possible way to make the drug discovery process more efficient is to ensure, at an early stage, that the tested compounds are diverse, representative and of high quality. In addition the biological evaluation systems have to be relevant and reliable. The diversity of the tested compounds could be ensured and the reliability of the biological assays improved by using Design Of Experiments (DOE) more frequently and effectively. However, DOE currently offers insufficient options for these purposes, so there is a need for new, tailor-made DOE strategies. The aim of the work underlying this thesis was to develop and evaluate DOE approaches for diverse compound selection and efficient assay optimisation. This resulted in the publication of two new DOE strategies; D-optimal Onion Design (DOOD) and Rectangular Experimental Designs for Multi-Unit Platforms (RED-MUP), both of which are extensions to established experimental designs.</p><p>D-Optimal Onion Design (DOOD) is an extension to D-optimal design. The set of possible objects that could be selected is divided into layers and D-optimal selection is applied to each layer. DOOD enables model-based, but not model-dependent, selections in discrete spaces to be made, since the selections are not only based on the D-optimality criterion, but are also biased by the experimenter’s prior knowledge and specific needs. Hence, DOOD selections provide controlled diversity.</p><p>Assay development and optimisation can be a major bottleneck restricting the progress of a project. Although DOE is a recognised tool for optimising experimental systems, there has been widespread unwillingness to use it for assay optimisation, mostly because of the difficulties involved in performing experiments according to designs in 96-, 384- and 1536- well formats. The RED-MUP framework combines classical experimental designs orthogonally onto rectangular experimental platforms, which facilitates the execution of DOE on these platforms and hence provides an efficient tool for assay optimisation.</p><p>In combination, these two strategies can help uncovering the crossroads between biology and chemistry in drug discovery as well as lead to higher information content in the data received from biological evaluations, providing essential information for well-grounded decisions as to the future of the project. These two strategies can also help researchers identify the best routes to take at the crossroads linking biological and chemical elements of drug discovery programs.</p>

New techniques and approaches for organic synthesis, purification and biological testing are enabling pharmaceutical industries to produce and test increasing numbers of compounds every year. Surprisingly, this has not led to more new drugs reaching the market, prompting two questions – why is there not a better correlation between their efforts and output, and can it be improved? One possible way to make the drug discovery process more efficient is to ensure, at an early stage, that the tested compounds are diverse, representative and of high quality. In addition the biological evaluation systems have to be relevant and reliable. The diversity of the tested compounds could be ensured and the reliability of the biological assays improved by using Design Of Experiments (DOE) more frequently and effectively. However, DOE currently offers insufficient options for these purposes, so there is a need for new, tailor-made DOE strategies. The aim of the work underlying this thesis was to develop and evaluate DOE approaches for diverse compound selection and efficient assay optimisation. This resulted in the publication of two new DOE strategies; D-optimal Onion Design (DOOD) and Rectangular Experimental Designs for Multi-Unit Platforms (RED-MUP), both of which are extensions to established experimental designs. D-Optimal Onion Design (DOOD) is an extension to D-optimal design. The set of possible objects that could be selected is divided into layers and D-optimal selection is applied to each layer. DOOD enables model-based, but not model-dependent, selections in discrete spaces to be made, since the selections are not only based on the D-optimality criterion, but are also biased by the experimenter’s prior knowledge and specific needs. Hence, DOOD selections provide controlled diversity. Assay development and optimisation can be a major bottleneck restricting the progress of a project. Although DOE is a recognised tool for optimising experimental systems, there has been widespread unwillingness to use it for assay optimisation, mostly because of the difficulties involved in performing experiments according to designs in 96-, 384- and 1536- well formats. The RED-MUP framework combines classical experimental designs orthogonally onto rectangular experimental platforms, which facilitates the execution of DOE on these platforms and hence provides an efficient tool for assay optimisation. In combination, these two strategies can help uncovering the crossroads between biology and chemistry in drug discovery as well as lead to higher information content in the data received from biological evaluations, providing essential information for well-grounded decisions as to the future of the project. These two strategies can also help researchers identify the best routes to take at the crossroads linking biological and chemical elements of drug discovery programs.

The development of a malaria vaccine is necessary for disease eradication. Successful vaccine candidates to date have targeted the asymptomatic, pre-erythrocytic stage of the disease, however even the most efficacious vaccines are only partially protective. Research undertaken in our laboratory has demonstrated that one such regimen, using an 8 week prime-boost viral vector approach of ChAd63 ME-TRAP and MVA ME-TRAP, induces sterile efficacy in 21% of vaccinees, with a key role identified for TRAP-specific CD8⁺ T cells. The work described in this thesis explores the most immunogenic regimen by which to administer these two pre-erythrocytic malaria vaccines. A shortening of the prime-boost interval from 8 to 4 weeks, and the addition of an extra ChAd63 ME-TRAP priming vaccination, both demonstrated improved T cell immunogenicity over the standard 8 week regimen. Further to this, novel assays were developed to aid the evaluation of vaccine-induced immune responses. Adaptations of the existing methodology for ELISpot analysis and to whole blood flow cytometry techniques, enabled more detailed analyses of paediatric vaccine-induced T cell responses in The Gambia. This work also permitted the comparison of vaccine immunogenicity in this paediatric population, with malaria-naïve and malaria-exposed adult vaccinees. The results suggest that vaccine-induced T cell responses in infants of 8 weeks and older are comparable to that of adults. A second approach involved the development of a novel functional assay. This assay quantitatively measured the in vitro inhibition of intrahepatic Plasmodium parasite development using T cells from ChAd63.MVA ME-TRAP vaccinated volunteers. The assay demonstrated the ability of CD8⁺ T cells to inhibit parasite development in a TRAP-specific manner, and provides a platform with which to further explore pre-erythrocytic immune responses.